TSL1502 / Tasly - LARVOL DELTA

A phase II study to evaluate the efficacy and safety of TSL-1502 capsules in breast cancer patients with germline BRCA mutations (ESMO 2024) - P2 | "Adult patients with HER2 negative locally advanced or metastatic breast cancer harboring germline BRCA 1/2 mutations were randomized (2:2:1) to receive TSL-1502 350mg QD, TSL-1502 500mg QD or chemotherapy by investigator's choice (eribulin, capecitabine or vinorelbine). TSL-1502 350mg and 500mg both showed preliminary anti-cancer activity in HER2 negative gBRCA 1/2 mutant breast cancer, while the higher dose showed potential better efficacy. Both dosages were well tolerated. The dose of 500mg is going to be developed for further studies."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • BRCA1 • BRCA2 • HER-2

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov) - P2 | N=125 | Recruiting | Sponsor: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • HER-2

A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA Mutations (clinicaltrials.gov) - P2 | N=125 | Not yet recruiting | Sponsor: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

New P2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • BRCA • HER-2